TNF and neoplasm: By contrast, tumor-targeted delivery of siTNFα by iRGD tandem peptides resulted in a reduction of TNFα levels by approximately 67% to a mean level of 93 pg/mL, which was statistically significant when compared with both scr control nanoparticles carrying siTNFα and with lipofectamine as positive control.